4.73
0.63%
-0.03
After Hours:
4.98
0.25
+5.29%
Zevra Therapeutics Inc stock is currently priced at $4.73, with a 24-hour trading volume of 140.91K.
It has seen a -0.63% decreased in the last 24 hours and a +1.94% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $4.80 pivot point. If it approaches the $4.70 support level, significant changes may occur.
Previous Close:
$4.76
Open:
$4.75
24h Volume:
140.91K
Market Cap:
$197.97M
Revenue:
$27.46M
Net Income/Loss:
$-46.05M
P/E Ratio:
-5.0319
EPS:
-0.94
Net Cash Flow:
$-33.83M
1W Performance:
-1.87%
1M Performance:
+1.94%
6M Performance:
+8.99%
1Y Performance:
-3.27%
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Name
Zevra Therapeutics Inc
Sector
Industry
Phone
888 958 1253
Address
1180 Celebration Boulevard, Suite 103, Celebration
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-17-23 | Initiated | Maxim Group | Buy |
Zevra Therapeutics Inc Stock (ZVRA) Latest News
Zevra Therapeutics, Inc. Expected to Earn Q2 2024 Earnings of ($0.46) Per Share (NASDAQ:ZVRA) - Defense World
Defense World
Q2 2024 EPS Estimates for Zevra Therapeutics, Inc. Cut by William Blair (NASDAQ:ZVRA) - MarketBeat
MarketBeat
Zevra Therapeutics (ZVRA) Stock Forecast and Price Target 2024 - MarketBeat
MarketBeat
Zevra Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.44) Per Share, Roth Capital Forecasts (NASDAQ:ZVRA) - Defense World
Defense World
Zevra Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.44) Per Share, Roth Capital Forecasts (NASDAQ:ZVRA) - Defense World
Defense World
Q2 2024 Earnings Estimate for Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Issued By Roth Capital - MarketBeat
MarketBeat
Zevra Therapeutics Inc Stock (ZVRA) Financials Data
Zevra Therapeutics Inc (ZVRA) Revenue 2024
ZVRA reported a revenue (TTM) of $27.46 million for the quarter ending December 31, 2023, a +170.26% rise year-over-year.
Zevra Therapeutics Inc (ZVRA) Net Income 2024
ZVRA net income (TTM) was -$46.05 million for the quarter ending December 31, 2023, a -72.00% decrease year-over-year.
Zevra Therapeutics Inc (ZVRA) Cash Flow 2024
ZVRA recorded a free cash flow (TTM) of -$33.83 million for the quarter ending December 31, 2023, a -79.86% decrease year-over-year.
Zevra Therapeutics Inc (ZVRA) Earnings per Share 2024
ZVRA earnings per share (TTM) was -$1.29 for the quarter ending December 31, 2023, a -65.38% decline year-over-year.
Zevra Therapeutics Inc Stock (ZVRA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Clifton R. LaDuane | CFO, Secretary & Treasurer |
Sep 06 '23 |
Buy |
4.96 |
1,000 |
4,959 |
15,309 |
Bode John B | Director |
Sep 05 '23 |
Buy |
5.13 |
10,000 |
51,333 |
20,000 |
Schafer Joshua | CCO & EVP, Bus. Development |
Sep 05 '23 |
Buy |
5.13 |
500 |
2,564 |
3,500 |
Watton Corey Michael | Director |
Jun 23 '23 |
Buy |
5.95 |
275 |
1,636 |
1,000 |
Watton Corey Michael | Director |
Jun 09 '23 |
Buy |
5.52 |
325 |
1,794 |
725 |
Watton Corey Michael | Director |
May 30 '23 |
Buy |
5.11 |
400 |
2,042 |
400 |
About Zevra Therapeutics Inc
Zevra Therapeutics, Inc., a rare disease therapeutics company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. Zevra Therapeutics, Inc. has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Cap:
|
Volume (24h):